Pharma & Biotech

Tubulis Secures €128 Million Series B2 Financing to Advance Novel ADC Pipeline for Cancer Treatment

(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences…

2 months ago

Health Canada Authorizes Probiotic Strain CLEPIUS™ for Alleviating Digestive Discomfort and Stress

(IN BRIEF) Health Canada has approved functional claims for Novonesis' probiotic strain CLEPIUS™, acknowledging its efficacy in alleviating symptoms of…

2 months ago

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May…

2 months ago

Breakthrough Study Shows Amlitelimab’s Long-lasting Effectiveness in Atopic Dermatitis Treatment

(IN BRIEF) In a groundbreaking Phase 2b study, amlitelimab demonstrates remarkable potential in maintaining treatment response for patients with moderate…

2 months ago

Boehringer Ingelheim and Sosei Heptares Forge Global Collaboration to Pioneer Precision Treatment for Schizophrenia

(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed…

2 months ago

Continuity and Strategy: Fresenius Management SE Proactively Extends CFO Sara Hennicken’s Mandate

(IN BRIEF) Fresenius Management SE has extended Sara Hennicken's term as Chief Financial Officer (CFO) until 2027, two years earlier…

2 months ago

FDA Gives Nod to Fresenius Kabi’s Tyenne®: A Dual-Format Tocilizumab Biosimilar Advancement

(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations.…

2 months ago

GSK Reports Positive Results from DREAMM-8 Phase III Trial of Blenrep in Multiple Myeloma Treatment

(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab…

2 months ago

Novo Nordisk Hosts Capital Markets Day to Share Progress on Strategic Aspirations 2025

(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The…

2 months ago

Biotech Acceleration: Evotec and Claris Ventures Unite to Propel Portfolio Companies Forward

(IN BRIEF) Evotec and Claris Ventures have formed a strategic partnership to accelerate the progress of biotech ventures in Claris's…

2 months ago